David MD - Mineralys Therapeutics, Chief Officer
| MLYS Stock | 12.70 0.21 1.68% |
Executive
David MD is Chief Officer of Mineralys Therapeutics, Common
| Age | 69 |
| Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Mineralys Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.3856) % which means that it has lost $0.3856 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6119) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics,'s management efficiency ratios could be used to measure how well Mineralys Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Mineralys Therapeutics,'s Total Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Nicole Esq | HCW Biologics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| JD Esq | Seres Therapeutics | 69 | |
| MD FAAP | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| David Ege | Seres Therapeutics | 49 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Alpa Parikh | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.39 |
Mineralys Therapeutics, Leadership Team
Elected by the shareholders, the Mineralys Therapeutics,'s board of directors comprises two types of representatives: Mineralys Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics,'s management team and ensure that shareholders' interests are well served. Mineralys Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McKean, Senior CMC | ||
| Adam Levy, CFO Secretary | ||
| Sarah Foster, Vice Resources | ||
| Danielle Bradbury, Senior Assurance | ||
| Jon Congleton, CEO Director | ||
| Cindy Berejikian, Executive Operations | ||
| Minji MBA, Chief Officer | ||
| Jessica Ibbitson, Senior Operations | ||
| Jeffrey Fellows, Senior Affairs | ||
| David MD, Chief Officer | ||
| MD MPH, Founder Chairman |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 624.7 M | ||||
| Shares Outstanding | 49.77 M | ||||
| Shares Owned By Insiders | 2.60 % | ||||
| Shares Owned By Institutions | 97.40 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Book | 2.62 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.